Complement activation during sepsis in humans

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 217-226

  Schreiber, Heike ^a   Rittirsch, Daniel ^a   Flierl, Michael ^a   Brueckner, Uwe ^a   Schneider, Marion ^b   Weiss, Manfred ^b   Gebhard, Florian ^a   Huber Lang, Markus ^a  

^a and Reconstructive Surgery ^*  (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934438397     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_15     Document Type: Conference Paper

References (25)

1. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med 348, 1546-1554 (2003).
2. B. Guidet, P. Aegerter, R. Gauzit, P. Meshaka, and D. Dreyfuss, CUB-Rea Study Group, Incidence and impact of organ dysfunctions associated with sepsis, Chest 127, 942-951 (2005).
3. B. J. Czermak, V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward, Protective effects of C5a blockade in sepsis, Nat Med 5, 788-792 (1999).
4. C. Gerard, Complement C5a in sepsis syndrome - too much of a good thing? N Engl J Med 348, 167-169 (2003).
5. M. Huber-Lang, J. V. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, J. T. Curnutte, and P. A. Ward, Role of C5a in multiorgan failure during sepsis. J Immunol 166, 1193-1199 (2001).
6. R. F. Guo, N. C. Riedemann, K. D. Bernacki, J. V. Sarma, I. J. Laudes, J. Reuben, E. M. Younkin, T. A. Neff, J. D. Paulauskis, F. S. Zetoune, and P. A. Ward, Neutrophil C5a receptor and the outcome in a rat model of sepsis, FASEB J Exp 17, 1889-1891 (2003).
7. M. Huber-Lang, E. M. Younkin, V. J. Sarma, S. R. McGuire, K. T. Lu, R. F. Guo, V. A. Padgaonkar, J. T. Curnutte, R. Erickson, and P. A. Ward, Complement-induced impairment of innate immunity during sepsis, J Immunol 169, 3223-3231 (2002).
8. M. Huber-Lang, N. C. Riedemann, V. J. Sarma, E. M. Younkin, S. R. McGuire, I. J. Laudes, K. T. Lu, R. F. Guo, T. A. Neff, V. A. Padgaonkar, J. Lambris, L. Spruce, D. Mastellos, F. S. Zetoune, and P. A. Ward, Protection of innate immunity by C5aR antagonist in septic mice, FASEB J 16, 1567-1574 (2002).
9. N. Riedemann, N. Tabriz, T. Barkhausen, M. Van Griensven, D. Kendoff, H. Pape, P. Ward, and C. Kretteck, PI3-Kinase/AKT pathway activation acts as a switch for C5a-induced effects on neutrophil IL-8 generation during inflammation, Shock 23, Suppl. 3, P120 (2005).
10. J. Cohen, The immunopathogenesis of sepsis, Nature. 420, 885-891 (2002).
11. R. S. Hotchkiss and I. E. Karl, The pathophysiology and treatment of sepsis. N Engl J Med 348, 138-150 (2003).
12. P. A. Ward, The dark side of C5a in sepsis, Nat Rev Immunol 4, 133-142 (2004).
13. R. C. Bone, R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655 (1992).
14. S. Stove, T. Welte, T. O. Wagner, A. Kola, A. Klos, W. Bautsch, and J. Kohl, Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3, 175-183 (1996).
15. T. Takakuwa, S. Endo, H. Nakae, M. Kikuchi, N. Baba, K. Inada, and M. Yoshida, Blood cytokine and complement levels in patients with sepsis. Res Commun Chem Pathol Pharmacol 84, 291-300 (1994).
16. H. Nakae, S. Endo, K. Inada, T. Takakuwa, and M. Yoshida, Chronological changes in the complement system in sepsis, Surg Today 26, 225-229 (1996).
17. K.A. Wichterman, A. E. Baue, and I. H. Chaudry, Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29, 189-201 (1980).
18. B. J. Czermak, M. Breckwoldt, Z. B. Ravage, M. Huber-Lang, H. Schmal, N. M. Bless, H. P. Friedl, and P. A. Ward, Mechanism of enhanced lung injury during sepsis. Am J Pathol 154, 1057-1065 (1999).
19. D. H. Hangen, J. H. Stevens, P. S. Satoh, E. W. Hall, P. T. O'Hanley, and T. A. Raffin, Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 46, 195-199 (1989).
20. A. Bengtson and M. Heideman, Anaphylatoxin formation of sepsis. Arch Surg 123, 645-649 (1988).
21. C. Leon, M. J. Rodrigo, A. Tomasa, M. T. Gallart, F. J. Latorre, J. Rius, and J. Brugues, Complement activation in septic shock due to gram-negative and gram-positive bacteria. Crit Care Med 10, 308-310 (1982).
22. N. P. Gerard and C. Gerard, The chemotactic receptor for human C5a anaphylatoxin. Nature 349, 614-617 (1991).
23. N. Naik, E. Giannini, L. Brouchon, and F. Boulay, Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J Cell Sci 110, 2381-2390 (1997).
24. M. Furebring, L. D. Hakannsson, P. Venge, B. Nilsson, and J. Sjölin, Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 6, 363-370 (2002).
25. I. J. Laudes, J. C. Chur, S. Sikranth, M. Huber-Lang, R. F. Guo, N. Riedemann, J. V. Sarma, A. H. Schmair, and P. A. Ward, Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 160, 1867-1875 (2002).